Employees: 10,900
Size AdaptHealth (AHCO) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.01B, the 2230th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.37 on 18 Nov 2026.
Performance Over six months the shares fell 29.7%, against +4.2% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 3.2% over the last twelve months (peer median +6.8%); the operating margin is 3.2% (peer median 9.2%).
Valuation It trades at 0.9× enterprise value to sales against a peer median of 1.8× (5th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.1 points below its cost of capital (7.6% WACC).
Credit AdaptHealth has 1 bond outstanding ($500M), rated B+ by the agencies and trading like BB- at a weighted spread of 204 bp.
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.15B | $3.24B | $3.26B | $3.20B | $2.97B |
| Revenue growth | — | 0% | +2% | +8% | — |
| Gross profit | $468M | $569M | $636M | $422M | $353M |
| EBITDA | $586M | $636M | $704M | $661M | $620M |
| Net income | -$404M | -$70.8M | $82.7M | -$679M | $69.3M |
| Free cash flow | $81.9M | $219M | $236M | $143M | -$17.6M |
| Capital expenditure | $497M | $382M | $306M | $337M | $391M |
| Total debt | $2.05B | $1.90B | $2.13B | $2.29B | $2.33B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AHCO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.8% | +2.0% | 2nd highest of 21 |
| 6-month return | -29.7% | +4.2% | 2nd lowest of 21 |
| Distance from 52-week high | -45.1% | -23.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | -3.2% | +6.8% | 5th lowest of 21 |
| Operating margin | 3.2% | 9.2% | 4th lowest of 21 |
| EV / Sales | 0.9× | 1.8× | 5th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 16.8% | 8.5% | 7th most demanding of 19 |
| Growth delivered (Del g) | +25.2% | +10.7% | 3rd highest of 19 |
| Hurdle (Req g minus delivered) | -8.3 pp | +0.8 pp | 7th least demanding of 19 |
| ROIC minus cost of capital | -5.1 pp | -0.3 pp | 5th lowest of 20 |
| EV / EBITDA | 5.1× | 10.7× | 3rd cheapest of 18 |
| Net debt / EBITDA | 3.4× | 1.6× | 7th most indebted of 19 |
| Bond spread | 204 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | 0.9× | 16.8% | +25.2% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 2.2× | 13.9% | +8.2% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 0.9× | 13.3% | +14.4% |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 0.7× | -9.0% | +1.6% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 1.8× | 6.3% | +7.7% |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 8.5× | 28.5% | +10.9% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 1.8× | -18.0% | +253.5% |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 1.2× | -5.1% | +5.3% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 6.5× | 32.4% | +10.5% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | 2.8× | n/a | n/a |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 1.5× | 20.7% | +19.4% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 2.5× | 7.3% | +18.9% |
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 1.3× | -4.7% | +12.2% |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 1.6× | 6.8% | +6.5% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 2.8× | 17.8% | +12.4% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 2.1× | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 0.4× | 3.5% | -5.1% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 0.9× | -19.6% | -4.0% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 2.6× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 1.0× | 9.7% | +2.1% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 5.6× | 36.6% | +31.6% |
AdaptHealth has 1 bond outstanding with $500M face value. The agencies rate it B+; its bonds trade like BB-. Weighted yield 6.65%, a spread of 204 bp over government bonds.